Guangdong Taiantang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 27, 2020 at 07:14 am EDT
Share
Guangdong Taiantang Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 2,523.823 million compared to CNY 2,757.075 million a year ago. Operating income was CNY 70.771 million compared to CNY 119.370 million a year ago. Net income was CNY 40.528 million compared to CNY 78.421 million a year ago. Basic earnings per share from continuing operations was CNY 0.05 compared to CNY 0.1 a year ago.
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.
GUANGDONG TAIANTANG PHARMACEUTICAL CO., LTD. 
